Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uz Antwerpen
Edegem, Belgium
Hans Prenen, MDRecruiting - Uz Gent
Ghent, Belgium
Sylvie Rottey, MDNot, yet, recruiting - Uz Leuven
Leuven, Belgium
Eric Van Cutsem, MDRecruiting
- Mayo Clinic
Jacksonville, Florida, United States
Not, yet, recruiting - Moffit Cancer Center
Tampa, Florida, United States
Kim Dae WonNot, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Nov 2021
- Primary completion
- 21 Aug 2023
- Completion
- 25 May 2038
- Last update posted
- 9 Mar 2022
- Registered enrollment
- 34
- Registry id
- NCT04991948
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.